11:51 AM
 | 
Nov 13, 2017
 |  BC Extra  |  Preclinical News

UCL, Autolus develop CARs against T cell malignancies that partially preserve normal T cells

A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell malignancies without wiping out normal T cells. Autolus Ltd. (London, U.K.) licensed the technology from University College London.

CAR T cells against B cell malignancies deplete both cancerous and normal B cells, which is considered a tolerable side effect. In contrast, complete T cell depletion causes unacceptable immunosuppression, which has limited development of...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >